Bain Capital Life Sciences Investors’s Disc Medicine IRON Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio IRON Stock Details IRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Hold	141,234	–	–	0.61%	17
2026 Q1	$9.03M	Buy	+141,234	New	+$9.8M	0.81%	17
2025 Q3	–	Sell	-583,500	Closed	-$30.9M	–	22
2025 Q2	$30.9M	Sell	583,500 -400,000	-41%	-$18.8M	3.87%	8
2025 Q1	$48.8M	Hold	983,500	–	–	7.22%	4
2024 Q4	$62.4M	Sell	983,500 -812,235	-45%	-$47M	7.33%	4
2024 Q3	$88.2M	Hold	1,795,735	–	–	9.18%	3
2024 Q2	$80.9M	Buy	1,795,735 +478,522	+36%	+$16.3M	8.89%	3
2024 Q1	$82M	Sell	1,317,213 -15,332	-1%	-$994K	6.59%	4
2023 Q4	$77M	Hold	1,332,545	–	–	7.38%	4
2023 Q3	$62.6M	Sell	1,332,545 -3	-0%	-$150	7%	5
2023 Q2	$59.2M	Sell	1,332,548 -658,366	-33%	-$23.4M	6.09%	5
2023 Q1	$42.2M	Buy	+1,990,914	New	+$44.4M	5.27%	4

Other funds holding IRON

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bain Capital Life Sciences Investors's IRON Position: Q2 2026 in Review

Bain Capital Life Sciences Investors held its Disc Medicine (IRON) position steady in Q2 2026 at 141,234 shares worth $10.3M. The position accounts for 0.61% of the portfolio, ranked #17.

Bain Capital Life Sciences Investors first reported a position in IRON in Q1 2023 and has held it in 12 quarters since. The position peaked at $88.2M in Q3 2024. 216 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

Bain Capital Life Sciences Investors held 141,234 shares of Disc Medicine worth $10.3M as of Q2 2026.
Bain Capital Life Sciences Investors left its Disc Medicine share count unchanged in Q2 2026.
Disc Medicine made up 0.61% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #17 holding.
Bain Capital Life Sciences Investors first reported a position in Disc Medicine in Q1 2023 and has held it in 12 quarters since.
Bain Capital Life Sciences Investors's Disc Medicine position peaked at $88.2M in Q3 2024.
216 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.